Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options ...

The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard ...

CNW/ - Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, has ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

A new study provides the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer ...

On an ordinary day in Brighton, Dheeresh Turnbull swabbed the inside of his cheek for science. He was healthy, with no ...

Get Instant Summarized Text (Gist) A prostate cancer screening program targeting individuals in the top decile of polygenic ...

In 2021, just over a third of men ages 55 to 69 had had a PSA (prostate-specific antigen) blood test to check for prostate cancer in the past year. That ...

Healthy lifestyle and dietary behaviors appeared associated with reduced all-cause and cardiovascular mortality among men with nonmetastatic prostate cancer, according to results of a prospective ...